Table 1 Baseline demography, clinical and medication characteristics of both groups
Group A (PLEX) (n = 50) | Group B (CYC) (n = 50) | p value | |
|---|---|---|---|
Demographic data (Mean ± SD) | |||
Age(years) | 25.7 ± 5.8 | 24 ± 5.6 | 0.129 |
Height /cm | 156.6 ± 3.5 | 158.1 ± 3 | 0.033 |
Weight /kg | 68.2 ± 8.4 | 66.6 ± 9.1 | 0.362 |
BMI (kg/m2) | 27.8 ± 3.5 | 26.7 ± 4 | 0.150 |
BMI classification [Number (%)] | |||
Normal | 9(18.0) | 17(34.0) | 0.189 |
Overweight | 29(58.0) | 23(46.0) | |
Obesity | 12(24.0) | 10(20.0) | |
Clinical data [Median (IQR)] | |||
Duration of SLE (months)* | 7.5(2–30) | 10(1–32) | 0.108 |
Duration of LN (months)* | 4(2–12) | 5(1–12) | 0.382 |
Total SLEDAI (mean ± SD) | 17.7 ± 2.2 | 10.2 ± 3.5 | < 0.001 |
Baseline medications (Mean ± SD) | |||
Prednisone (mg/day) | 12.4 ± 7.3 | 10.8 ± 5.7 | 0.240 |
Hydroxychloroquine mg/day | 200 ± 0 | 200 ± 0 | NA |
Maintenance medications [Number (%)] | |||
AZA | 18(36.0) | 26(52.0) | 0.107 |
Cyclophosphamide | 0(0.0) | 10 (20.0) | 0.001 |
MMF | 32(64.0) | 14(28.0) | < 0.001 |